Tags

Type your tag names separated by a space and hit enter

Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Int J Neurosci. 2011 Nov; 121(11):605-13.IJ

Abstract

OBJECTIVE

Assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off (EODWO), comparing immediate and delayed switch (IS, DEL) to levodopa/carbidopa/entacapone (LCE).

BACKGROUND

LCE treatment improves motor function in PD patients with EODWO. Correlations with QoL have not been previously assessed.

METHODS

A 16-week, prospective, randomized, multicenter, open-label study in PD subjects on stable levodopa/carbidopa (LC) doses with EODWO. The IS subjects switched to LCE at baseline; DEL subjects at week 4. The primary efficacy variable was UPDRS III score (baseline to week 4). QoL measurements (PDQUALIF, PDQ-39) were assessed at baseline, weeks 4, 8, and study endpoint.

RESULTS

The intent-to-treat population comprised 350/359 patients (IS, n = 177; DEL, n = 173). A significant decrease in UPDRS III scores at week 4 was observed (IS, 3.7U, p < .0001; DEL, 1.8U, p = .0018). Group differences favored IS (1.9U, p = .0148). At week 8, IS subjects had significant total score decreases in PDQUALIF (2.5U, p = .0133) and PDQ-39 (5.8U, p = .0001). In the mobility and activities of daily living PDQ-39 subdomains, IS subjects had significantly larger week 4 decreases (versus DEL p = .0331 and p = .0125, respectively). Adverse events included diarrhea (14.5%), nausea (12.3%), and dizziness (8.4%).

CONCLUSION

The IS provided greater motor improvement at week 4 and improved QoL at week 8.

Authors+Show Affiliations

Department of Neurology, Division of Movement Disorders, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. marklew@usc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21843110

Citation

Lew, Mark F., et al. "Immediate Versus Delayed Switch From Levodopa/carbidopa to Levodopa/carbidopa/entacapone: Effects On Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off." The International Journal of Neuroscience, vol. 121, no. 11, 2011, pp. 605-13.
Lew MF, Somogyi M, McCague K, et al. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. Int J Neurosci. 2011;121(11):605-13.
Lew, M. F., Somogyi, M., McCague, K., & Welsh, M. (2011). Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. The International Journal of Neuroscience, 121(11), 605-13. https://doi.org/10.3109/00207454.2011.598982
Lew MF, et al. Immediate Versus Delayed Switch From Levodopa/carbidopa to Levodopa/carbidopa/entacapone: Effects On Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off. Int J Neurosci. 2011;121(11):605-13. PubMed PMID: 21843110.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. AU - Lew,Mark F, AU - Somogyi,Monique, AU - McCague,Kevin, AU - Welsh,Mickie, AU - ,, Y1 - 2011/08/16/ PY - 2011/8/17/entrez PY - 2011/8/17/pubmed PY - 2012/8/8/medline SP - 605 EP - 13 JF - The International journal of neuroscience JO - Int J Neurosci VL - 121 IS - 11 N2 - OBJECTIVE: Assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off (EODWO), comparing immediate and delayed switch (IS, DEL) to levodopa/carbidopa/entacapone (LCE). BACKGROUND: LCE treatment improves motor function in PD patients with EODWO. Correlations with QoL have not been previously assessed. METHODS: A 16-week, prospective, randomized, multicenter, open-label study in PD subjects on stable levodopa/carbidopa (LC) doses with EODWO. The IS subjects switched to LCE at baseline; DEL subjects at week 4. The primary efficacy variable was UPDRS III score (baseline to week 4). QoL measurements (PDQUALIF, PDQ-39) were assessed at baseline, weeks 4, 8, and study endpoint. RESULTS: The intent-to-treat population comprised 350/359 patients (IS, n = 177; DEL, n = 173). A significant decrease in UPDRS III scores at week 4 was observed (IS, 3.7U, p < .0001; DEL, 1.8U, p = .0018). Group differences favored IS (1.9U, p = .0148). At week 8, IS subjects had significant total score decreases in PDQUALIF (2.5U, p = .0133) and PDQ-39 (5.8U, p = .0001). In the mobility and activities of daily living PDQ-39 subdomains, IS subjects had significantly larger week 4 decreases (versus DEL p = .0331 and p = .0125, respectively). Adverse events included diarrhea (14.5%), nausea (12.3%), and dizziness (8.4%). CONCLUSION: The IS provided greater motor improvement at week 4 and improved QoL at week 8. SN - 1563-5279 UR - https://www.unboundmedicine.com/medline/citation/21843110/Immediate_versus_delayed_switch_from_levodopa/carbidopa_to_levodopa/carbidopa/entacapone:_effects_on_motor_function_and_quality_of_life_in_patients_with_Parkinson's_disease_with_end_of_dose_wearing_off_ L2 - https://www.tandfonline.com/doi/full/10.3109/00207454.2011.598982 DB - PRIME DP - Unbound Medicine ER -